Preferred Label : FEC Followed by Pertuzumab/Trastuzumab/Docetaxel Regimen;
NCIt synonyms : Fluorouracil/Epirubicin/Cyclophosphamide Followed by Pertuzumab/Trastuzumab/Docetaxel; FEC Followed by Docetaxel/Trastuzumab/Pertuzumab; Fluorouracil/Epirubicin/Cyclophosphamide Followed by Pertuzumab Trastuzumab Docetaxel; FEC Followed by Pertuzumab Trastuzumab Docetaxel;
NCIt related terms : FEC-THP (Docetaxel) (trastuzumab-zerc); FEC-THP (Docetaxel); FEC-THP (Docetaxel) (trastuzumab-dkst); FEC-THP (Docetaxel) (trastuzumab-anns); FEC-THP (Docetaxel) (trastuzumab-qyyp); FEC-THP (Docetaxel) (trastuzumab-pkrb); FEC-THP (Docetaxel) (trastuzumab-herw); FEC-THP (Docetaxel) (trastuzumab-dttb); FEC-THP (Docetaxel) (trastuzumab-strf);
NCIt definition : A regimen consisting of fluorouracil, epirubicin and intravenous cyclophosphamide,
followed by pertuzumab, trastuzumab and docetaxel, used as a neoadjuvant or adjuvant
treatment for HER-2/neu-positive breast cancer.;
NCIt note : Source: NCCN Guidelines 2017;
NCI Metathesaurus CUI : CL525014;
Codes from synonyms : 129407; 64059; 129116; 129019; 128922; 128825; 129310; 129213; 140132;
Origin ID : C138038;
UMLS CUI : C4527345;
Semantic type(s)
- chemotherapy_regimen_has_component
- concept_is_in_subset
